Quarterly report · Q2
2385.TEDINET S100SUZ2
Period2023-07-01 → 2023-12-31
Filed2024-02-14
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 46
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥2.8bn | 2023-07-01 → 2023-12-31 | Cons. | Net sales |
| Revenue | ¥8.1bn | 2022-07-01 → 2023-06-30 | Cons. | Net sales (5-year summary) |
| Revenue | ¥4.2bn | 2022-07-01 → 2022-12-31 | Cons. | Net sales |
| Operating income | −¥455m | 2023-07-01 → 2023-12-31 | Cons. | Operating income |
| Operating income | ¥345m | 2022-07-01 → 2022-12-31 | Cons. | Operating income |
| Ordinary income | −¥449m | 2023-07-01 → 2023-12-31 | Cons. | Ordinary income |
| Ordinary income | ¥727m | 2022-07-01 → 2023-06-30 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥345m | 2022-07-01 → 2022-12-31 | Cons. | Ordinary income |
| Profit before tax | −¥449m | 2023-07-01 → 2023-12-31 | Cons. | Income before income taxes |
| Profit before tax | ¥345m | 2022-07-01 → 2022-12-31 | Cons. | Income before income taxes |
| Net income (owners) | −¥488m | 2023-07-01 → 2023-12-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥452m | 2022-07-01 → 2023-06-30 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥209m | 2022-07-01 → 2022-12-31 | Cons. | Profit loss attributable to owners of parent |
| Net income | −¥489m | 2023-07-01 → 2023-12-31 | Cons. | Profit loss |
| Net income | ¥213m | 2022-07-01 → 2022-12-31 | Cons. | Profit loss |
| Total assets | ¥7.1bn | at 2023-12-31 | Cons. | Assets |
| Total assets | ¥8.2bn | at 2023-06-30 | Cons. | Assets |
| Total assets | ¥8.0bn | at 2022-12-31 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥702m | at 2023-12-31 | Cons. | Liabilities |
| Total liabilities | ¥1.1bn | at 2023-06-30 | Cons. | Liabilities |
| Net assets / equity | ¥6.4bn | at 2023-12-31 | Cons. | Net assets |
| Net assets / equity | ¥7.2bn | at 2023-06-30 | Cons. | Net assets |
| Net assets / equity | ¥6.9bn | at 2022-12-31 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥4.7bn | at 2023-12-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥5.9bn | at 2023-06-30 | Cons. | Cash and deposits |
| Cash & equivalents | ¥4.7bn | at 2023-12-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥5.9bn | at 2023-06-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥5.5bn | at 2022-12-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥6.0bn | at 2022-06-30d | Cons. | Cash and cash equivalents |
| Operating cash flow | −¥967m | 2023-07-01 → 2023-12-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | −¥102m | 2022-07-01 → 2023-06-30 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | −¥328m | 2022-07-01 → 2022-12-31 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥10m | 2023-07-01 → 2023-12-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | ¥160m | 2022-07-01 → 2023-06-30 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥27m | 2022-07-01 → 2022-12-31 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥260m | 2023-07-01 → 2023-12-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥130m | 2022-07-01 → 2023-06-30 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥130m | 2022-07-01 → 2022-12-31 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥-18.65 | 2023-07-01 → 2023-12-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥1.5 | 2023-10-01 → 2023-12-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥17.27 | 2022-07-01 → 2023-06-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥8 | 2022-07-01 → 2022-12-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥7.47 | 2022-10-01 → 2022-12-31d | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 89.9% | at 2023-12-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 84.6% | at 2023-06-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 84.4% | at 2022-12-31 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 49
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2023-07-01 → 2023-12-31 | −¥10m |
| Reconciling Itemsreconciling | revenue external | 2023-07-01 → 2023-12-31 | ¥900,000 |
| Reconciling Itemsreconciling | revenue intersegment | 2023-07-01 → 2023-12-31 | −¥11m |
| Reconciling Itemsreconciling | segment profit | 2023-07-01 → 2023-12-31 | −¥156m |
| jpcrp040300-q2r_E05367-000Clinical Evidence Servicereportable segment | revenue | 2023-07-01 → 2023-12-31 | ¥176m |
| jpcrp040300-q2r_E05367-000Clinical Evidence Servicereportable segment | revenue external | 2023-07-01 → 2023-12-31 | ¥176m |
| jpcrp040300-q2r_E05367-000Clinical Evidence Servicereportable segment | segment profit | 2023-07-01 → 2023-12-31 | ¥1m |
| jpcrp040300-q2r_E05367-000Functional Cosmetic Retailingreportable segment | revenue | 2023-07-01 → 2023-12-31 | ¥779m |
| jpcrp040300-q2r_E05367-000Functional Cosmetic Retailingreportable segment | revenue external | 2023-07-01 → 2023-12-31 | ¥779m |
| jpcrp040300-q2r_E05367-000Functional Cosmetic Retailingreportable segment | segment profit | 2023-07-01 → 2023-12-31 | −¥72m |
| jpcrp040300-q2r_E05367-000Functional Food Retailingreportable segment | revenue | 2023-07-01 → 2023-12-31 | ¥1.4bn |
| jpcrp040300-q2r_E05367-000Functional Food Retailingreportable segment | revenue external | 2023-07-01 → 2023-12-31 | ¥1.4bn |
| jpcrp040300-q2r_E05367-000Functional Food Retailingreportable segment | revenue intersegment | 2023-07-01 → 2023-12-31 | ¥3m |
| jpcrp040300-q2r_E05367-000Functional Food Retailingreportable segment | segment profit | 2023-07-01 → 2023-12-31 | −¥270m |
| jpcrp040300-q2r_E05367-000Functional Material Developmentreportable segment | revenue | 2023-07-01 → 2023-12-31 | ¥165m |
| jpcrp040300-q2r_E05367-000Functional Material Developmentreportable segment | revenue external | 2023-07-01 → 2023-12-31 | ¥157m |
| jpcrp040300-q2r_E05367-000Functional Material Developmentreportable segment | revenue intersegment | 2023-07-01 → 2023-12-31 | ¥8m |
| jpcrp040300-q2r_E05367-000Functional Material Developmentreportable segment | segment profit | 2023-07-01 → 2023-12-31 | −¥701,000 |
| jpcrp040300-q2r_E05367-000Health Care Support Servicereportable segment | revenue | 2023-07-01 → 2023-12-31 | ¥337m |
| jpcrp040300-q2r_E05367-000Health Care Support Servicereportable segment | revenue external | 2023-07-01 → 2023-12-31 | ¥337m |
| jpcrp040300-q2r_E05367-000Health Care Support Servicereportable segment | segment profit | 2023-07-01 → 2023-12-31 | ¥43m |
| —segment total | revenue | 2023-07-01 → 2023-12-31 | ¥2.9bn |
| —segment total | revenue external | 2023-07-01 → 2023-12-31 | ¥2.8bn |
| —segment total | revenue intersegment | 2023-07-01 → 2023-12-31 | ¥11m |
| —segment total | segment profit | 2023-07-01 → 2023-12-31 | −¥299m |
| Reconciling Itemsreconciling | revenue | 2022-07-01 → 2022-12-31 | −¥2m |
| Reconciling Itemsreconciling | revenue external | 2022-07-01 → 2022-12-31 | ¥900,000 |
| Reconciling Itemsreconciling | revenue intersegment | 2022-07-01 → 2022-12-31 | −¥3m |
| Reconciling Itemsreconciling | segment profit | 2022-07-01 → 2022-12-31 | −¥155m |
| jpcrp040300-q2r_E05367-000Clinical Evidence Servicereportable segment | revenue | 2022-07-01 → 2022-12-31 | ¥258m |
| jpcrp040300-q2r_E05367-000Clinical Evidence Servicereportable segment | revenue external | 2022-07-01 → 2022-12-31 | ¥258m |
| jpcrp040300-q2r_E05367-000Clinical Evidence Servicereportable segment | segment profit | 2022-07-01 → 2022-12-31 | ¥32m |
| jpcrp040300-q2r_E05367-000Functional Cosmetic Retailingreportable segment | revenue | 2022-07-01 → 2022-12-31 | ¥2.0bn |
| jpcrp040300-q2r_E05367-000Functional Cosmetic Retailingreportable segment | revenue external | 2022-07-01 → 2022-12-31 | ¥2.0bn |
| jpcrp040300-q2r_E05367-000Functional Cosmetic Retailingreportable segment | segment profit | 2022-07-01 → 2022-12-31 | ¥398m |
| jpcrp040300-q2r_E05367-000Functional Food Retailingreportable segment | revenue | 2022-07-01 → 2022-12-31 | ¥1.4bn |
| jpcrp040300-q2r_E05367-000Functional Food Retailingreportable segment | revenue external | 2022-07-01 → 2022-12-31 | ¥1.4bn |
| jpcrp040300-q2r_E05367-000Functional Food Retailingreportable segment | segment profit | 2022-07-01 → 2022-12-31 | −¥18m |
| jpcrp040300-q2r_E05367-000Functional Material Developmentreportable segment | revenue | 2022-07-01 → 2022-12-31 | ¥279m |
| jpcrp040300-q2r_E05367-000Functional Material Developmentreportable segment | revenue external | 2022-07-01 → 2022-12-31 | ¥277m |
| jpcrp040300-q2r_E05367-000Functional Material Developmentreportable segment | revenue intersegment | 2022-07-01 → 2022-12-31 | ¥3m |
| jpcrp040300-q2r_E05367-000Functional Material Developmentreportable segment | segment profit | 2022-07-01 → 2022-12-31 | ¥43m |
| jpcrp040300-q2r_E05367-000Health Care Support Servicereportable segment | revenue | 2022-07-01 → 2022-12-31 | ¥314m |
| jpcrp040300-q2r_E05367-000Health Care Support Servicereportable segment | revenue external | 2022-07-01 → 2022-12-31 | ¥314m |
| jpcrp040300-q2r_E05367-000Health Care Support Servicereportable segment | segment profit | 2022-07-01 → 2022-12-31 | ¥45m |
| —segment total | revenue | 2022-07-01 → 2022-12-31 | ¥4.2bn |
| —segment total | revenue external | 2022-07-01 → 2022-12-31 | ¥4.2bn |
| —segment total | revenue intersegment | 2022-07-01 → 2022-12-31 | ¥3m |
| —segment total | segment profit | 2022-07-01 → 2022-12-31 | ¥500m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 441
| Item | Context | Value | Unit |
|---|---|---|---|
| Net cash provided by used in investment activities | Prior1YTDDuration | -27023000 | JPY |
| Net cash provided by used in investment activities | CurrentYTDDuration | -9933000 | JPY |
| Cash dividends paid fin cf | Prior1YTDDuration | -129936000 | JPY |
| Cash dividends paid fin cf | CurrentYTDDuration | -131230000 | JPY |
| Payments from changes in ownership interests in subsidiaries that do not result in change in scope of consolidation fin cf | Prior1YTDDuration | － | JPY |
| Payments from changes in ownership interests in subsidiaries that do not result in change in scope of consolidation fin cf | CurrentYTDDuration | -129262000 | JPY |
| Net cash provided by used in financing activities | Prior1YTDDuration | -129936000 | JPY |
| Net cash provided by used in financing activities | CurrentYTDDuration | -260492000 | JPY |
| Net increase decrease in cash and cash equivalents | Prior1YTDDuration | -484857000 | JPY |
| Net increase decrease in cash and cash equivalents | CurrentYTDDuration | -1237203000 | JPY |
| Cash and cash equivalents | Prior2YearInstant | 6017253000 | JPY |
| Cash and cash equivalents | Prior1YearInstant | 5945854000 | JPY |
| Cash and cash equivalents | Prior1QuarterInstant | 5532396000 | JPY |
| Cash and cash equivalents | CurrentQuarterInstant | 4708650000 | JPY |
| Advertising expenses sga | Prior1YTDDuration | 478715000 | JPY |
| Advertising expenses sga | CurrentYTDDuration | 538949000 | JPY |
| Research and development expenses sga | Prior1YTDDuration | 20122000 | JPY |
| Research and development expenses sga | CurrentYTDDuration | 16248000 | JPY |
| Depreciation sga | Prior1YTDDuration | 7942000 | JPY |
| Depreciation sga | CurrentYTDDuration | 10605000 | JPY |
| Provision of allowance for doubtful accounts sga | Prior1YTDDuration | -4180000 | JPY |
| Provision of allowance for doubtful accounts sga | CurrentYTDDuration | -31000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q2r_E05367-000ClinicalEvidenceServiceReportableSegmentsMember | 258436000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q2r_E05367-000HealthCareSupportServiceReportableSegmentsMember | 314241000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q2r_E05367-000FunctionalCosmeticRetailingReportableSegmentsMember | 1960299000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q2r_E05367-000FunctionalFoodRetailingReportableSegmentsMember | 1413450000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q2r_E05367-000FunctionalMaterialDevelopmentReportableSegmentsMember | 276511000 | JPY |
| Revenues from external customers | Prior1YTDDuration_ReportableSegmentsMember | 4222939000 | JPY |
| Revenues from external customers | Prior1YTDDuration_ReconcilingItemsMember | 900000 | JPY |
| Revenues from external customers | Prior1YTDDuration | 4223839000 | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q2r_E05367-000ClinicalEvidenceServiceReportableSegmentsMember | － | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q2r_E05367-000HealthCareSupportServiceReportableSegmentsMember | － | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q2r_E05367-000FunctionalCosmeticRetailingReportableSegmentsMember | － | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q2r_E05367-000FunctionalFoodRetailingReportableSegmentsMember | － | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q2r_E05367-000FunctionalMaterialDevelopmentReportableSegmentsMember | 2547000 | JPY |
| Transactions with other segments | Prior1YTDDuration_ReportableSegmentsMember | 2547000 | JPY |
| Transactions with other segments | Prior1YTDDuration_ReconcilingItemsMember | -2547000 | JPY |
| Transactions with other segments | Prior1YTDDuration | － | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q2r_E05367-000ClinicalEvidenceServiceReportableSegmentsMember | 258436000 | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q2r_E05367-000HealthCareSupportServiceReportableSegmentsMember | 314241000 | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q2r_E05367-000FunctionalCosmeticRetailingReportableSegmentsMember | 1960299000 | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q2r_E05367-000FunctionalFoodRetailingReportableSegmentsMember | 1413450000 | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q2r_E05367-000FunctionalMaterialDevelopmentReportableSegmentsMember | 279058000 | JPY |
| Net sales | Prior1YTDDuration_ReportableSegmentsMember | 4225486000 | JPY |
| Net sales | Prior1YTDDuration_ReconcilingItemsMember | -1647000 | JPY |
| Net sales | Prior1YTDDuration | 4223839000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q2r_E05367-000ClinicalEvidenceServiceReportableSegmentsMember | 31518000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q2r_E05367-000HealthCareSupportServiceReportableSegmentsMember | 45490000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q2r_E05367-000FunctionalCosmeticRetailingReportableSegmentsMember | 398195000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q2r_E05367-000FunctionalFoodRetailingReportableSegmentsMember | -17884000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |